Erleada
Chemical Name | apalutamide |
Dosage Form | Tablet (oral; 60 mg) |
Drug Class | Inhibitors |
System | Male reproductive |
Company | Janssen Biotech |
Approval Year | 2018 |
Indication
- Erleada is indicated for the treatment of patients with metastatic castration-sensitive prostate cancer.
- Erleada is indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.